Business Description
GRI Bio Inc
NAICS : 541714
SIC : 2834
ISIN : US3622AW4030
Total Employee Number:
5Description
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 190.48 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 86.3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 30.84 | |||||
9-Day RSI | 35.52 | |||||
14-Day RSI | 37.83 | |||||
3-1 Month Momentum % | -5.71 | |||||
6-1 Month Momentum % | -63.33 | |||||
12-1 Month Momentum % | -94.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.21 | |||||
Quick Ratio | 14.21 | |||||
Cash Ratio | 13.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -728.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -236.38 | |||||
ROA % | -158.07 | |||||
ROIC % | -7806.43 | |||||
3-Year ROIIC % | 1609.59 | |||||
ROC (Joel Greenblatt) % | -12708.14 | |||||
ROCE % | -235.34 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.26 | |||||
Price-to-Tangible-Book | 0.26 | |||||
EV-to-EBIT | 0.73 | |||||
EV-to-Forward-EBIT | -0.17 | |||||
EV-to-EBITDA | 0.73 | |||||
EV-to-Forward-EBITDA | -0.17 | |||||
EV-to-FCF | 0.65 | |||||
| Price-to-Net-Current-Asset-Value | 0.26 | |||||
| Price-to-Net-Cash | 0.27 | |||||
Earnings Yield (Greenblatt) % | 136.99 | |||||
FCF Yield % | -396.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GRI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
GRI Bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -79.473 | ||
| Beta | -0.8232 | ||
| 3-Year Sharpe Ratio | -1.72 | ||
| 3-Year Sortino Ratio | -1.93 | ||
| Volatility % | 117.57 | ||
| 14-Day RSI | 37.83 | ||
| 14-Day ATR ($) | 0.138128 | ||
| 20-Day SMA ($) | 1.9385 | ||
| 12-1 Month Momentum % | -94.78 | ||
| 52-Week Range ($) | 1.695 - 80.36 | ||
| Shares Outstanding (Mil) | 1.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
GRI Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
GRI Bio Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-14 | In 33 days | ||
| General meeting for 2026 | 2026-08-13 11:00 | In 33 days | ||
| First quarter earnings results for 2026 | 2026-05-13 | 2.28 (+1.33%) | ||
| Annual report for 2025 | 2026-01-30 | 3.32 (-9.54%) | ||
| 0.0357143:1 Stock Split | 2026-01-26 | 5.64 (+0.40%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 47.32 (-7.65%) | ||
| Second quarter earnings results for 2025 | 2025-08-14 | 36.40 (+3.17%) | ||
| General meeting for 2025 | 2025-08-13 11:00 | 35.42 (+8.12%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 41.16 (-2.00%) |
Show
Entries
GRI Bio Inc Frequently Asked Questions
What is GRI Bio Inc(GRI)'s stock price today?
The current price of GRI is $1.73. The 52 week high of GRI is $80.36 and 52 week low is $1.70.
When is next earnings date of GRI Bio Inc(GRI)?
The next earnings date of GRI Bio Inc(GRI) is 2026-08-14 Est..
Does GRI Bio Inc(GRI) pay dividends? If so, how much?
GRI Bio Inc(GRI) does not pay dividend.
Guru Commentaries on NAS:GRI
No articles.
Press Release
Articles on GRI Bio Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers